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Abstract
T cell development and maturation involve a variety of defined and coordinated developmental stages under the control 
of a variety of signaling networks. They function as the major mediator in cell-based immunity that defends against 
pathogen infections and executes immune surveillance against tumor cells. Protein kinase B (PKB, also called Akt) is central 
to multiple signaling pathways and transduces extracellular signals to dictate cellular responses towards proliferation, 
migration, anti-apoptosis, and maintenance of metabolic homeostasis. Although the prosurvival function of PKB was 
thought to be responsible for most of the functions regulated by PKB, emerging evidence has started to dissect its role 
in immunomodulation. More importantly, hyperactivation of PKB in cancer stroma frequently occurs in patients treated 
clinically with targeted cancer therapies, where it acts as a key mediator involved in the trapping of host immune cells in 
the vicinity of tumors, which supports cancer cell invasion and the escape of cancer cells from host immune surveillance. 
Encouragingly, recent studies have shown that inhibition of PKB improves the recognition of cancer cells by the host 
immune system, indicating a potential clinical strategy to rekindle the suppressed host immune response through the 
specific targeting of PKB. In this review, we explore how PKB signaling contributes to T cell development and cellular 
immune responses and discuss the mechanistic roles that PKB plays in the creation of immunosuppressive conditions and 
the escaping of immune recognition in the microenvironment of cancer.
Introduction to PKB
PKB is a serine/threonine kinase of the AGC protein kinase 
subfamily (1). It comprises three highly sequence-identical iso-
forms in mammals, PKBα, PKBβ, and PKBγ, that are ubiquitously 
expressed in all cell types with slight differences in tissue dis-
tribution (2). In response to a variety of stimuli including growth 
factors and hormones that trigger rapid activation of lipid kinase 
phosphoinositide 3 kinase (PI3K), the secondary messenger mol-
ecule Phosphatidylinositol (3,4,5)-trisphosphate (PIP3) is gener-
ated (3), which in turn recruits PKB to the plasma membrane 
where it is phospho-activated by phosphoinositide-dependent 
kinase-1 (PDK1) (on Thr308). Maximal kinase activity of PKB is 
achieved through mammalian target of rapamycin complex 2 
(mTORC2)– or DNA-dependent protein kinase (DNAPK)–medi-
ated phosphorylation on Ser473 (1,4). Therefore, PKB is a direct 
functional downstream target of PI3K under the control of PDK1 
and mTORC2 or DNAPK (Figure 1). Genetic studies in knockout 
mice have indicated a primary function of PKB as a promoter 
of cell proliferation and survival (5,6). Consistent with its physi-
ological role in development, PKB has been found to be hyper-
activated in many types of cancer. Inhibition of PKB activity not 
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only attenuates tumor growth (7,8) but also local invasion and 
metastasis (9) resulting from crosstalk with other oncogenic 
signaling such as mitogen-activated protein kinase (MAPK) (10), 
transforming growth factor-β (TGF-β) (11,12), vascular endothe-
lial growth factor (VEGFR) (13), and (ephrin) Eph (14). In this 
regard, PKB is an attractive target for cancer therapies and sev-
eral promising inhibitors of PKB are currently being validated 
in clinical trials including MK-2206 (15,16), Perifosin (17–21), and 
RX-0201 (22).
PKB-Regulated T Cell Development
PKB at the β-Selection Checkpoint
T cell development can broadly be split into four steps: 1) com-
mon lymphoid progenitors (CLPs) derived from bone-marrow 
hematopoietic cells migrate to the thymus where they act as 
early T cell progenitors (ETPs); 2)  ETPs then autonomously 
undergo four stages of transition from double-negative expres-
sion of CD4/CD8 (DN, CD4-CD8-) to double-positive expression 
(DP, CD4+CD8+). This represents the maturation stage of thy-
mocytes, and these cells express low levels of pre-T cell recep-
tor (TCR); 3)  mature “single-positive” cells are then selected 
by MHC-induced positive and negative selection and 4) subse-
quently emigrate to the periphery in response to sphingosine-
1-phosphate (S1P) stimulation for final maturation (Figure 2).
At the first key checkpoint (the transition from DN3 to DN4 
cells before CD4 and CD8 are simultaneously expressed), ETPs 
undergo rearrangement of the β-chain of the pre-TCR (23,24), a 
fundamental event to prime the structural properties for pairing 
with pre-TCR α-chain on the surface of the thymocytes, a pro-
cess defined as β-selection. A number of early studies showed 
that Notch activity plays a crucial role in determining which 
thymocytes with functional pre-TCRs enter into the DN4 stage 
(25–27). Importantly, this prosurvival effect of Notch signaling is 
abolished upon PI3K/PKB inhibition, and expression of consti-
tutively active PKB efficiently rescues Notch loss–induced apop-
tosis by bypassing PI3K signaling, indicating a stringent role 
for PKB in the control of pre-T cell survival (28). A recent study 
uncovered that Hes1, the downstream target of Notch signaling, 
mediates elevated PKB signaling through targeting phosphatase 
and tensin homolog (PTEN) (29). Similarly, DN3 cells with PKB 
depletion undergo apoptosis in response to pre-TCR stimulation 
(30). In fact, downregulation of PKB activity leads to substantial 
developmental blockage at the DN3 stage, indicating the failure 
of differentiation driven by Notch signaling (31). In line with the 
role of PKB in promoting β-selection, some PKB targets such 
as Glycogen synthase kinase 3 (GSK3)/T-cell factor 1 (TCF-1)/β-
catenin (32–34) and cAMP response element-binding protein 
(CREB) (35) were also shown to participate in signaling regu-
lation at this checkpoint. This raises the question of whether 
these events are also dependent on PKB activity, which needs 
future investigation.
PKB Activation During Thymic Selection and 
Maturation
When thymocytes pass β-selection and enter the DP (CD4+CD8+) 
stage, characterized by low-level expression of pre-TCR, the cells 
need to vigorously proliferate. Previous studies showed that this 
was enabled by activated PKB that upregulated levels of Bcl-XL, 
a member of the anti-apoptotic Bcl-2 family (36,37). DP thymo-
cytes that moderately recognize self-peptide-major histocom-
patibility complex (MHC) complexes survive and are induced 
to differentiate (positive selection), whereas those that recog-
nize self-peptide-MHC complexes with high affinity/avidity 
are induced toward cell death (negative selection) to eliminate 
potentially toxic T cells. These two programs of thymic selection 
are coupled with TCR-regulated cell survival through PKB, which 
selectively modulates an apoptotic effector downstream of TCR 
signaling, the orphan nuclear receptor Nur77, and thus drives 
naïve T cell maturation (38).
Following functional postselection of thymocytes expressing 
either CD4 or CD8 protein, these single-positive (SP, CD4+CD8- 
or CD4-CD8+) thymocytes migrate to the periphery where they 
further develop into different functional T cell populations. S1P 
signaling is required to ensure that only mature SP thymocytes 
are permitted to enter the periphery. Loss of S1P receptor 1 
(S1P1) expression on mature SP thymocytes blocks the thymic 
egress of these cells because of inhibition of the chemotactic 
activity mediated by S1P/S1P1 signaling (39). Interestingly, PKB-
dependent phosphorylation of S1P1 is required for S1P1-mediated 
chemotaxis (40). In addition, S1P1 expression is transcriptionally 
regulated by Krüppel-like factor 2 (KLF2) which is also required 
for cell trafficking (41) and whose expression is stringently con-
trolled by forkhead box O (FoxO) family member FoxO1, a well-
characterized phospho-target of PKB (42,43). Therefore, PKB/
FoxO1/KLF2 signaling is likely central in determining a complete 
mature state of the thymocytes that egress from the thymus at 
the late stage of T cell development. C-C chemokine receptor 7 
(CCR7) and CCR9 were also shown to determine the fate of ETPs 
homing to thymus (44,45); however, it is not clear whether this 
early step in T cell development is also regulated by PKB/FoxO1 
signaling.
Owing to the global importance of PKB in supporting cell 
proliferation and survival and overcoming apoptosis, it is not 
surprising that PKB acts as a gatekeeper to secure the smooth 
transition through these developmental checkpoints. This role 
of PKB is unlikely to be restricted only to T cell development. 
A few studies have already shown the similar functions for PKB 
in other types of immune cells such as B cells (46–48), dendritic 
cells (49–52), macrophages (53,54), and neutrophils (55). Thus, 
PKB is crucial in regulating immune cell development.
Figure 1. Molecular mechanism of protein kinase B (PKB) signaling transduction. 
Extracellular signals such as chemokines, cytokines, and growth factors bind to 
their membrane receptors and activate corresponding axes. Intracellular media-
tors such as PDK1 and mTORC2 kinases are simultaneously activated and trans-
duce messages to the central hub PKB. As a “tertiary” messenger, PKB directs 
cell fate through phospho-regulation of its substrates, most of which tran-
scriptionally control cell proliferation, survival and migration. DNAPK = DNA-
dependent protein kinase; mTORC2 = mammalian target of rapamycin complex 
2; PDK1 = phosphoinositide-dependent kinase 1.
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PKB-Dependent Regulation of T Cell 
Functionality
The Impact of PKB on CD8+ T Cell Metabolism and 
Response
mTOR-directed involvement of PI3K/PKB signal transduc-
tion has been shown to be pivotal to glucose metabolism (56). 
Upon stimulation, the fate of CD8+ T cells (effector or memory) 
is determined by cytokines, particularly interleukin 2 (IL-2). 
Previously it was shown that stimulation of T cells with anti-CD3 
and anti-CD28 induces glucose uptake and aerobic glycolysis 
(the Warburg effect) in a PKB-dependent but IL-2–independent 
manner (57). In primary CD8+ T cells with depleted TCR signal-
ing, attenuated glucose metabolism through reduced glycolysis 
is triggered by decreased expression of glucose transporter 1 
(Glut1) (58), whose expression level and stabilized membrane 
translocation require PKB activity (59,60). PKB-regulated glu-
cose metabolism was further supported by follow-up studies 
that showed that constitutive activation of PKB may override 
the influence of cytokine stimulation on Glut1 activation (61,62). 
Consistently, upon reactivation of memory CD8+ T cells, the 
metabolic switch from basal fatty acid oxidation and mitochon-
drial oxidative phosphorylation to aerobic glycolysis and lipid 
synthesis, needed for rapid acquisition of effector functionality 
such as the production of IFNγ, is regulated by PKB rather than 
mTORC1 (63). Thus, PKB is a crucial signaling cascade responsi-
ble for elevated metabolic rate in T cells.
The activities of many transcriptional factors that are crucial 
for determining cell fate and behavior are post-translationally 
modulated by PKB (9). A recent study showed that inhibition of 
PKB decreases mRNA levels of several key molecules responsible 
for T cell effector functions, including granzymes, perforin, Fas 
ligand, INFγ, and cytokine receptors such as IL-12R, indicating 
that TCR-mediated transcriptional programs that determine 
effector or memory cell differentiation are strictly dependent 
on PKB (64). This seems to be in agreement with a recent study 
showing that conversion of CD8+ T cells from memory to effector 
state requires PKB activation (63).
CD8+ T cells responding to stimuli follow three distinct 
phases: clonal expansion, contraction, and establishment of 
memory. As the metabolic and survival regulator of T cells, it 
is not surprising that PKB dictates the magnitude of CD8+ T 
cell memory through controlling dynamic alterations in prolif-
eration and apoptotic rates via its downstream mediator FoxO 
family members (65). Once the infecting pathogens are cleared, 
autonomous apoptosis occurs in the majority of pathogen-spe-
cific effector CD8+ T cells through the PKB/FoxO axis, whereas 
a small percentage will develop into memory CD8+ T cells for 
rapid response to secondary stimulation in the future (66). This 
is similar to the role of PKB during thymic selection, where TCR 
priming leads to massive cell death in absence of PKB signal-
ing. Taken together, these data support a concept that PKB is an 
essential regulator along the immunometabolic signaling path-
way in T cells, but with differentially defined functional speci-
ficity in different T cell subpopulations in response to diverse 
stimuli.
PKB Regulates CD4+ T Cell Differentiation
Peripheral naïve CD4+ T cells mature and differentiate in response 
to antigenic stimulation into distinct functional subsets with 
specific roles in the regulation of the immune response. The fate 
of the cells is determined by individual stimuli, most of which 
Figure 2. Key steps and checkpoints during T cell development. APC = antigen-presenting cell; CLP = common lymphoid progenitor; CTL = cytotoxic T lymphocytes; 
DN = double negative; DP = double positive; HSC = hematopoietic stem cell; MPP = multipotent progenitor; SP = single positive; Th = helper T cells; Treg = regulatory 
T cells.
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are from interleukin family members. Each specialized CD4+ T 
cell lineage exhibits functionally dominant transcriptional pro-
grams driven by unique pools of transcription factors such as 
T-box binding protein (T-bet), GATA family member GATA3, fork-
head box P3 (FoxP3), and RAR-related orphan receptor gamma 3 
(RORγ3), representing T helper cell 1 (Th1), Th2, regulatory T cell 
(Treg), and Th17 lineages, respectively (Figure 3A). PKB activity is 
tightly associated with the differentiation state of CD4+ T cells, 
and numerous studies have shown that it contributes substan-
tially to the regulation of signaling events at transcriptional and 
translational levels, under both physiological and pathological 
settings (67–69). In the scenario of global control, PKB-mediated 
direct phosphorylation of FoxO1 and FoxO3a leads to cytoplas-
mic sequestration, thus inhibiting their DNA binding activity 
(70). In T cells, FoxO1 and FoxO3a transcriptionally activate T-bet 
(71,72) and FoxP3 (73–76), which inversely associate with PKB 
activity.
In most cases, it is the expression ratio among the transcrip-
tion factors, rather than the overexpression or suppression 
of a single protein, that determines the differentiation fate of 
CD4+ T cell lineage. This obviously raises the question of how 
this balance of transcription factors is maintained. Recent stud-
ies have started to uncover the potential mechanisms. Under 
inflammatory conditions, elevated TGF-β signaling promotes 
Treg cell functionality through promotion of FoxP3 but restrains 
Th17 phenotype by decreasing levels of RAR-related orphan 
receptor gamma t (RORγt) (77). Opposing expression patterns 
of FoxP3 and RORγt in the same cell population are possibly, at 
least partly, because of a physical inhibitory interaction (78,79). 
When extracellular conditions favor a transition to Th17 dif-
ferentiation, IL-6 may counteract FoxP3-mediated inhibition 
of RORγt. Interestingly, a recent study also showed that PKB/
mTORC1-mediated activation of ribosomal protein S6 kinase 
2 (S6K2) promotes RORγt nuclear translocation through direct 
coupling (80). Moreover, to enhance the maintenance of Treg 
differentiation, expression of GATA3 maintains high levels of 
FoxP3 but inhibits T-bet and RORγt through as yet undefined 
mechanisms (81). By contrast, to maintain a Th1 phenotype the 
functionality of GATA3 can be physically repressed by T-bet by 
directly interfering with its DNA binding capacity (82). While it 
is not yet clear whether PKB can directly affect the function of 
GATA3, studies have shown that PKB can directly phosphorylate 
and functionally influence GATA1 (83) and GATA2 (84). Given the 
high degree of sequence similarity in the DNA-binding domain 
adjacent to the distal zinc-finger motif (85) among GATA family 
members (Figure 3B), it would be interesting to investigate if PKB 
can influence Th2 cell differentiation directly through GATA3 by 
bypassing FoxO. Therefore, under the global surveillance of PKB/
FoxO signaling axis, a precisely regulated interplay between the 
transcriptional signature molecules seems to be the dominating 
factor that determines the differentiation of CD4+ T cell lineages 
(Figure 3C).
The Role of PKB in Escaping 
Immunosurveillance in Cancer
PKB Controls the Expression of Chemokines
The mTOR/PI3K/PKB signaling pathway is highly deregulated 
in human diseases, such as cancer, which require an aber-
rant demand of metabolic rate. The surrounding environment 
of tumors, the cancer stroma, is the fundamental resource for 
nutrient supply to cancer cells. Cancer stroma consists of a vari-
ety of cell types, including cancer-associated fibroblasts (CAF), 
endothelial cells, myeloid cells, lymphocytes, and pericytes (86), 
many of which are actively recruited to the cancer environment 
and utilized by cancer cells to satisfy the increased metabolic 
demand. Consistent with the pivotal role of PKB during immune 
cell development, extensive studies have revealed that PKB 
stimulates aerobic glycolysis in many types of cancer cells (87–
90) (comprehensively reviewed by Ward et al. [91]). Intriguingly, 
PKB-regulated cancer cell metabolism can be further enhanced 
Figure 3. Regulation of CD4+ T cell differentiation. A) CD4+ T cells are differentiated into four main lineages with distinct transcriptional programs in response to 
stimulation of different chemokines. B) Sequence alignment of human GATA family members. C) Protein kinase B (PKB)–mediated regulation of the transcriptional 
determinants towards terminal differentiation of CD4+ T cells. APC = antigen presenting cell; MHC = major histocompatibility complex; TCR = T cell receptor.
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when cancer cells encounter disturbing situations such as a 
stiffened extracellular matrix (92), indicating that cancer cells 
are capable of autonomous adaption to their niche environment 
through PKB-promoted metabolism.
CAFs and endothelial cells are responsible for tumor initia-
tion and establishment of tumor vascular network essential for 
local invasiveness and nutrient/oxygen supply (93,94). It is now 
becoming evident that the immune cells in the vicinity of the 
cancer niche also markedly impact aspects of cancer biology, 
including tumor cell metastasis to distant organs, cancer angio-
genesis, cancer immune regulation, and overcoming metabolic 
stress (95). Directional trafficking of immune cells to the cancer 
niche is a chemotactic process triggered mainly by chemokines 
secreted from cancer cells in a gradient-dependent manner (96), 
which results in the entire tumor niche acting as a core regula-
tor that modulates survival, invasion, and immune-suppression 
(97).
Although PI3K is a key regulator of chemoattractants (such 
as PIP3) (98), PKB signaling can potently control cell migration 
in different settings (9). Inflammatory conditions in the vicin-
ity of developing tumors, particularly chronic inflammation, are 
positively associated with tumor progression. Pivotal pathways 
that regulate tumor-associated inflammation, such as the tumor 
necrosis factor (TNF)/IκB kinase (IKK)/nuclear factor κB (NF-κB) 
axis, can be induced and enhanced through tumor-express-
ing molecules, whose activation, in turn, promotes malignant 
transformation of tumor cells. Upregulation of tumor-associ-
ated inflammatory factors is often orchestrated by transcrip-
tional events driven by NF-κB signaling, which is tightly under 
the control of crosstalk between PKB and the IKK signalosome 
(99–102). By pairing to CCR6, C-C chemokine ligand 20 (CCL20) 
has been shown to be a key mediator in many inflammatory 
diseases including cancer (103–105). Migration of Th17 cells 
towards developing tumors is driven by CCL20, and this requires 
PKB activation. Mechanistically, the transcriptional regulation 
of CCL20 is mediated through nuclear translocation and acti-
vation of NF-κB (106–108), a transcriptional complex negatively 
regulated by its endogenous inhibitor IκB, which is degraded by 
PKB-mediated phosphorylation. Similarly, PKB-mediated activa-
tion of NF-κB regulates many chemokines during chemotactic 
migration of cells such as dendritic cells via CCL19 (109); CTL 
cells, Th2 cells, and macrophages via CCL5 (110); and Treg cells 
via CCL17 and CCL22 (111,112). The chemokine-mediated 
immune cell migration to the cancer niche is summarized in 
Figure 4. Undoubtedly, most of these chemoattractants are also 
expressed by different subsets of immune cells that coopera-
tively stimulate local inflammation in cancer stroma. It is also 
known that PKB-regulated NF-κB transcriptionally activates 
Snail, an epithelial-mesenchymal transition inducer that pro-
motes cell migration in a context-dependent manner (113,114). 
Snail is capable of upregulating pro-inflammatory cytokines 
such as IL-1, IL-6, and IL-8, which enhance the chemotactic 
migration of both immune cells and metastatic cancer cells 
(115). Moreover, activation of Snail also elevates levels of CCL2 
in melanoma (116). PKB activates Snail by phospho-inhibition of 
GSK3, an upstream inhibitory kinase that prevents the nuclear 
translocation of Snail (117).
Likewise, the expression of chemokine receptors may also 
be controlled by PKB. For example, in prostate cancer with 
PTEN loss, ablation of PKB results in a sizable decrease in C-X-C 
chemokine receptor 4 (CXCR4) at both the transcriptional and 
translational levels, which consequently inhibits metastatic 
spread by disrupting the CCL12/CXCR4 network (118). As well 
as regulating chemokines, NF-κB is also thought to regulate 
chemokine receptors such as CCR5 and CCR7 (119). Activation 
of chemokine and cytokine signaling can mediate a feed-for-
ward signaling loop that enhances intracellular PKB activity, a 
mechanism that has been widely demonstrated in the signal-
ing network of receptor tyrosine kinase/PI3K/PKB in cancer. In 
a xenograft model of breast cancer, CCL5 secreted from mesen-
chymal stem cells activated PKB signaling in circulating tumor 
cells to promote extravasation from the circulation and colo-
nization at distal organs (120). Therefore, PI3K/PKB activation 
and upregulation of inflammatory chemokines and receptors 
can reciprocally control cell-cell communication in the cancer 
environment through modulation of chemotactic migration. 
In fact, the functional interaction between PKB and IκB/NF-κB 
has been shown to create a protumoral microenvironment at 
inflammatory sites where particularly chronic inflammation 
persistently occurs (121). The resulting inflammatory responses 
Figure 4. Chemokine-mediated immune cell trafficking to tumor vicinity. Individual chemokines expressed by cancer cells are highlighted in pink boxes, and the cor-
responding chemokine receptors expressed by immune cells are highlighted in the green boxes. Note: Many chemokines are also expressed by different immune cells 
peritumorally or intratumorally to regulate local inflammation and cell-cell interaction. Because of its complex nature, this aspect is not reflected in the simplified car-
toon. Open arrows indicate migratory direction. CCL = C-C chemokine ligand; CCR = C-C chemokine receptor; CTL = cytotoxic T lymphocytes; CXCR = C-X-C chemokine 
receptor; DC = dendritic cells; MacroΦ = macrophage; Th = T helper cell; Treg = regulatory T cells.
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can augment tumor cell growth and metastasis through a com-
bination of accelerated cell cycle, increased genomic instability, 
and cytoskeleton remodeling-induced motility.
PKB Supports Tumor Cells to Escape from 
Immunosurveillance
For several decades, the infiltration and accumulation of 
immune cells in the tumor vicinity was thought to be detri-
mental to cancer cells. However, all types of immune cells are 
found in different tumors, regardless of the cancer type, origin, 
and residing organs. These immune cells differentially impact 
tumor development by mediating the interactions between can-
cer cells and the environment. Clinical trial data has shown that 
infiltration of CD8+ T cells, natural killer (NK) cells, and Th1 cells 
within tumors is associated with a good prognosis in most types 
of cancer, whereas infiltration of Th2, Treg, Th17 cells, mac-
rophages, and neutrophils is associated with poor prognosis 
(122–126). This implies that certain immune cell types may have 
a tumor-promoting role during cancer development. Indeed, 
tumor cells that survive intrinsic and/or extrinsic stress, includ-
ing host immune defense, neglect the immune detection and 
gain tolerance (127).
Despite the impacts of myeloid-derived suppressor cells 
(MDSC) and Treg-mediated T cell anergy (128,129), several mech-
anisms for the escape from host immunosurveillance by cancer 
cells have been suggested, including impaired antigen-present-
ing activity, unfavorable cytokine and chemokine secretion, and 
direct suppression of immune cell function by interaction of 
inhibitory molecules on cancer cell surface with immune cell 
surface markers (130,131). These immune resistance mecha-
nisms may arise from local immunological stress, whereby 
selected cancer cells that survive the innate immune response 
undergo stress-induced genetic or epigenetic modifications 
to adapt to the tumor microenvironment and evade immune 
detection. This organized process, also called cancer immu-
noediting (132), mechanistically mimics the clonal evolution of 
cancer cells that underlies the acquisition of resistance to thera-
peutic drugs, which typically results in more aggressive tumors. 
Thus, it is evident that the inflammatory factors expressed by 
both immune cells and tumor cells in a PKB-regulated manner, 
can contribute to create immunosuppressive conditions.
Cell-cell interaction-triggered T cell dysfunction is mainly 
mediated through inhibitory molecular pairing between pro-
grammed death ligands 1 and 2 (PD-L1/2) (133). These members 
of the B7 protein family are expressed on the surface of infiltrat-
ing cells and cancer cells, and their receptor, programmed death 
1 (PD-1), is expressed on the surface of activated T cells, mac-
rophages, dendritic cells, B cells, and NK cells (134). Under physi-
ological conditions, when PD-1 binds to their ligands, negative 
signals are delivered into the T cells that attenuate their activi-
ties by inhibiting TCR-mediated proliferation to prevent tissue 
damage from unfavorable immune responses (135). This mech-
anism is appropriated by cancer cells to directly induce T cell 
apoptosis through a similar interaction. Interestingly, expres-
sion of PD-L1 in tumor cells is tightly associated, or regulated 
by PKB. In human gliomas, PTEN loss leads to increased immu-
noresistance through upregulation of PD-L1 in a PKB activation–
dependent manner (136). Selective inhibition of PKB with small 
molecule inhibitor (Akt inhibitor III) was shown to decrease the 
expression level of PD-L1, which was mediated through PKB-
regulated mTORC1/S6K1 signaling. This is in agreement with the 
finding that interferons may also activate PI3K/PKB/mTOR/S6K 
pathway (137), though the molecular mechanisms underlying 
PD-L1 upregulation need further investigation. Similarly, this 
PKB-dependent PD-L1 expression pattern is also observed in 
colorectal cancer (138).
Further evidence for the role of PKB in regulation of PD-L1 
come from the investigation of PD-L1 expression in triple-
negative human breast cancer, where specifically targeting 
PKB activity with the pharmacological inhibitor MK-2206 was 
shown to substantially downregulate PD-L1 at the transcrip-
tional level (139). Independent studies also showed a potential 
mechanism for PD-L1 downregulation at the translational level 
by PKB in both breast and prostate cancer (140), mutant BRAF-
harboring melanomas (141), and pancreatic cancer (142). Clearly, 
the molecular mechanisms explaining how PKB mediates PD-L1 
expression are the missing piece of the puzzle. This links to an 
even more complex situation in which each PKB isoform may 
have a different impact, as many studies have shown oppos-
ing roles of PKB isoforms in driving tumor metastasis in differ-
ent types of cancer (9). Nonetheless, the emerging data clearly 
shows that PKB actively participates in tumor cell–mediated 
immunosuppression, at least through two distinct paths via 
promoting chemokine/cytokine expression and upregulating 
PD-L1 expression. Therefore, targeting the PKB signaling node 
may enable reviving of the host immune response in clinical 
cancer therapy.
T Cell Functionality Upon PKB Inhibition in the 
Cancer Niche
Despite the robust inhibitory effect on cancer cell proliferation 
and glucose uptake, evidence from recent studies also suggested 
that inhibition of PKB restored and enhanced physiological 
functionalities of T cells in the tumor microenvironment. In a 
mouse model of adoptive cell therapy, pharmacological inhibi-
tion of PKB with an allosteric inhibitor (AKT inhibitor VIII) repro-
grammed the transcriptional events in CD8+ tumor-infiltrating 
lymphocytes (TIL) into phenotypic memory cells (143). In addi-
tion, this phenotype was coupled with improved survival of 
transferred antitumor TIL in vivo and an enhanced antitumor 
effect in the mouse model. This in vivo observation was further 
supported in a grafted myeloma mouse model, in which inhibi-
tion of PKB with the same inhibitor blocked the differentiation 
of CD8+ T cells, improved the expansion of CD8+ T cells, and was 
associated with superior antitumor effects in the mice (144). 
Moreover, inhibition of the PKB pathway with MK-2206 selec-
tively suppressed Treg proliferation and enhanced the antitu-
mor effect of a tumor-specific vaccine in a mouse model (145). 
Thus, these findings further support the concept that targeting 
PKB enables tumor-specific lymphocytes to exert antitumor 
immunity in immunotherapy for advanced cancer.
Conclusions and Perspectives
Emerging evidence highlights the importance of the tumor 
microenvironment as a critical regulator that determines the 
outcome of clinic cancer therapy. This impact is fundamen-
tally because of the complex network of cell-cell interactions 
between tumor cells, immune cells, and the extracellular 
matrix. Therapeutic strategies that block the intercellular com-
munication of this network have shown promising clinical 
benefit to the patients, and cancer immunotherapy strategies 
aimed at reviving functional immunosurveillance, in particular 
in combination with other targeted therapies, have become an 
effective approach in cancer clinic. For example, recent clinical 
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studies with PD-1– and PD-L1–blocking antibodies highlight the 
substantial therapeutic strategy in cancer patients with incur-
able tumors or relapsed tumors post-therapy (146,147). In addi-
tion, blocking CCL22 inhibits the trafficking of CCR4-expressing 
Treg cells to the metastatic lesion (148). Targeting tumorigenic 
inflammation by inhibition of CCL2 restrains CCR2-expressing 
immune cells, such as monocytes in bone marrow (149), which 
decreased the inflammatory risk from recruited tumor-associ-
ated macrophages (150) and led to suppression of metastasis in 
syngeneic mouse models of metastatic breast cancer.
Hyperactivation of PKB may represent a fundamental hall-
mark of cancer that contributes to resistance to both chemo-
therapy and radiotherapy (151,152). As described above, CCL22 
is under transcriptional regulation of NK-κB, which is acti-
vated by PKB-mediated degradation of IκB. CCL2 synthesis is 
regulated by the Snail transcription factor, which is negatively 
controlled by GSK3, a direct substrate of PKB. Thus, downregula-
tion of PKB activity can theoretically interfere with the CCL22/
CCR4 and CCL2/CCR2 axes to block tumor-directed trafficking 
of immunosuppressive Treg and monocytes. The mechanisms 
of PKB-promoted immune evasion of cancer cells have been 
demonstrated by increased resistance to CD8+ T cell–mediated 
apoptosis (145,153,154), overriding death receptor signaling 
(155), strengthening energetic metabolism (156), and enforcing 
the functionality of immunosuppressive Treg cells (157,158). 
Therefore, inhibition of PI3K/PKB can principally suppress the 
tumor-driven immunosuppressive effect through remodeling of 
the entire tumor microenvironment.
Current cancer therapeutic strategies invariably induce drug 
resistance in the clinic. Among many potential mechanisms, 
the disruption of negative feedback loops and compensatory 
activation of other oncogenic signaling pathways are two major 
causes. In melanoma patients bearing an activating mutation 
on BRAF (V600E), inhibition of mutant BRAF with vemurafenib 
or dabrafenib dramatically reduces MAPK activity and improves 
median response duration (159). Vemurafenib therapy not only 
inhibits tumor growth through tumor intrinsic mechanisms but 
also decreases the population of immunosuppressive myeloid 
derived suppressor cells (MDSCs) (160) and increases levels of 
tumor infiltration of CD8+ T cells (161). However, this immunore-
sponsive phenotype is diminished at the time of tumor repro-
gression, and a comparative study implies that the intratumoral 
T cell infiltration is dependent on tumor sensitivity to vemu-
rafenib (162). Importantly, at this resistance developing stage, 
inhibition of mutant BRAF spontaneously strengthens PI3K/PKB 
signaling through various mechanisms, as well as NF-κB (163), 
which coincides with reduced recognition of melanoma cells by 
immune cells. Given the regulatory role of PKB in production of 
inflammatory factors, it is foreseeable that PKB will prove to be a 
contributor to immunounresponsivess in melanomas resistant 
to vemurafenib therapy. Thus, a combinatory approach target-
ing oncogenic signaling while stimulating immune response is 
emerging as a more effective strategy (164).
As well as its critical role in chemotactic migration and 
chemokine/cytokine-mediated cell-cell interaction, PKB also 
participates in cellular adhesion to the extracellular matrix, 
which in parallel further enhances cell survival and migra-
tory potential driven by local immune tolerance. This is largely 
attributable to the impacts on the activity of adhesion-associ-
ated molecules including focal adhesion kinase (165), EphA2 
(14), Ron (166,167), Zyxin (168), CD34 (169), and CTNND2 (170), 
et  al. Encouragingly, emerging data show improved antitumor 
response of T cells by inhibiting PKB signaling (171). Given 
the broad impact of the PKB cascade on many aspects during 
cancer development, functional dissection of its emerging role 
in antagonizing immunosurveillance is likely to contribute sub-
stantially to cancer immunotherapeutic strategies.
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